BR112022011388A2 - Métodos para tratar ou prevenir asma alérgica administrando um antagonista de il-33 e/ou um antagonista de il-4r - Google Patents

Métodos para tratar ou prevenir asma alérgica administrando um antagonista de il-33 e/ou um antagonista de il-4r

Info

Publication number
BR112022011388A2
BR112022011388A2 BR112022011388A BR112022011388A BR112022011388A2 BR 112022011388 A2 BR112022011388 A2 BR 112022011388A2 BR 112022011388 A BR112022011388 A BR 112022011388A BR 112022011388 A BR112022011388 A BR 112022011388A BR 112022011388 A2 BR112022011388 A2 BR 112022011388A2
Authority
BR
Brazil
Prior art keywords
antagonist
allergic asthma
methods
administering
interleukin
Prior art date
Application number
BR112022011388A
Other languages
English (en)
Portuguese (pt)
Inventor
Goulaouic Helene
Haddad El-Bdaoui
HAMON Sara
Harel Sivan
Kalliolias Georgios
Ruddy Marcella
Original Assignee
Sanofi Biotechnology
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology, Regeneron Pharma filed Critical Sanofi Biotechnology
Publication of BR112022011388A2 publication Critical patent/BR112022011388A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112022011388A 2019-12-23 2020-12-22 Métodos para tratar ou prevenir asma alérgica administrando um antagonista de il-33 e/ou um antagonista de il-4r BR112022011388A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962952996P 2019-12-23 2019-12-23
US202062964970P 2020-01-23 2020-01-23
PCT/US2020/066559 WO2021133776A1 (en) 2019-12-23 2020-12-22 Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist

Publications (1)

Publication Number Publication Date
BR112022011388A2 true BR112022011388A2 (pt) 2022-08-30

Family

ID=74191948

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011388A BR112022011388A2 (pt) 2019-12-23 2020-12-22 Métodos para tratar ou prevenir asma alérgica administrando um antagonista de il-33 e/ou um antagonista de il-4r

Country Status (11)

Country Link
US (1) US20230340101A1 (enExample)
EP (1) EP4081544A1 (enExample)
JP (2) JP2023508360A (enExample)
KR (1) KR20220119446A (enExample)
CN (1) CN115151568A (enExample)
AU (1) AU2020415382A1 (enExample)
BR (1) BR112022011388A2 (enExample)
CA (1) CA3162507A1 (enExample)
IL (1) IL294066A (enExample)
MX (1) MX2022007958A (enExample)
WO (1) WO2021133776A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
CA3236201A1 (en) * 2021-11-11 2023-05-19 Regeneron Pharmaceuticals, Inc. Treatment of lung disease based upon stratification of polygenic risk score for interleukin 33 (il-33)
KR20250017964A (ko) * 2023-07-28 2025-02-04 재단법인 아산사회복지재단 혈액 단백체를 이용한 생물학적 제제에 대한 천식 치료 반응성 예측을 위한 바이오마커 및 이의 용도
WO2025088063A2 (en) * 2023-10-24 2025-05-01 Sanofi Systems and methods for monitoring a medicament dosing schedule
CN117949666B (zh) * 2024-01-12 2025-07-15 首都医科大学附属北京同仁医院 一种预测或评估抗IL-4Rα单抗在治疗鼻黏膜2型炎症相关鼻病疗效的标志物、方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
JO3532B1 (ar) * 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
AR108263A1 (es) * 2016-05-03 2018-08-01 Bayer Pharma AG Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo
HUE067888T2 (hu) * 2016-09-01 2024-11-28 Regeneron Pharma Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
TWI784988B (zh) * 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
BR112022000740A2 (pt) * 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r

Also Published As

Publication number Publication date
MX2022007958A (es) 2022-10-07
CN115151568A (zh) 2022-10-04
JP2026068738A (ja) 2026-04-22
AU2020415382A1 (en) 2022-08-18
CA3162507A1 (en) 2021-07-01
EP4081544A1 (en) 2022-11-02
JP2023508360A (ja) 2023-03-02
KR20220119446A (ko) 2022-08-29
IL294066A (en) 2022-08-01
US20230340101A1 (en) 2023-10-26
WO2021133776A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
BR112022011388A2 (pt) Métodos para tratar ou prevenir asma alérgica administrando um antagonista de il-33 e/ou um antagonista de il-4r
BR112022002442A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
BR112019010646A2 (pt) métodos de tratamento de condições inflamatórias
BR112022000581A2 (pt) Métodos para tratamento de alergia e intensificação de imunoterapia específica dos alergénos através da administração de um antagonista de il-4r
BR112021021195A2 (pt) Métodos para tratamento ou prevenção da asma pela administração de um antagonista de il-33
BR112014011896A2 (pt) agentes de rnai, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr)
BR112016024379A2 (pt) variantes ldlr e seu uso em composições para reduzir os níveis de colesterol
MX2021013327A (es) Anticuerpo anti-receptor cgrp para usarse en tratar o prevenir dolor de cabeza por migra?a.
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
NO20092905L (no) Doseringsregime for COMT-ihibitorer
BR112015003590A8 (pt) Métodos para tratamento ou prevenção da asma por administração de um antagonista de il-4r
BR112021021908A2 (pt) Composições úteis no tratamento da leucodistrofia metacromática
BR112023004020A2 (pt) Métodos para tratamento de asma em indivíduos pediátricos através da administração de um antagonista de il-4r
BR112016030541A2 (pt) métodos para o tratamento de infecções fúngicas
BR112016020919A2 (pt) redução dos níveis ou da atividade sistêmica de células t regulatórias para o tratamento de doença e lesão do snc
BR112020015915A8 (pt) Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
BR112021019262A2 (pt) Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose
CR20170259A (es) Terapias de envenenamiento y composiciones farmacéuticas, sistemas y equipos relacionados
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
MX376691B (es) Composición farmaceutica que comprende un antagonista de il-4r para tratar una infección cutánea.
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
ZA202110111B (en) Methods and compositions for treating liver disorders
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BR112022015363A2 (pt) Uso de um antagonista do receptor de interleucina-4 (il-4r), composição farmacêutica e recipiente para tratar dermatite atópica (da) ou melhorar um parâmetro associado à da em um indivíduo
BR112016001781A2 (pt) inibidores de rorc2 e métodos de uso dos mesmos

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: REGENERON PHARMACEUTICALS, INC. (US) ; SANOFI BIOTECHNOLOGY (FR)